Compare OPXS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPXS | ACET |
|---|---|---|
| Founded | 1987 | 1947 |
| Country | United States | United States |
| Employees | 72 | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.5M | 77.3M |
| IPO Year | 2009 | 2017 |
| Metric | OPXS | ACET |
|---|---|---|
| Price | $13.97 | $8.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $16.10 | ★ $48.33 |
| AVG Volume (30 Days) | 45.4K | ★ 70.9K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.55 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $24,530,000.00 | N/A |
| Revenue This Year | $39.17 | N/A |
| Revenue Next Year | $0.53 | N/A |
| P/E Ratio | $61.00 | ★ N/A |
| Revenue Growth | ★ 17.63 | N/A |
| 52 Week Low | $9.74 | $0.46 |
| 52 Week High | $17.76 | $9.47 |
| Indicator | OPXS | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 60.63 | 57.64 |
| Support Level | $12.46 | $7.02 |
| Resistance Level | $13.68 | $8.93 |
| Average True Range (ATR) | 0.78 | 0.42 |
| MACD | 0.08 | 0.08 |
| Stochastic Oscillator | 78.05 | 74.85 |
Optex Systems Holdings Inc manufactures optical sighting systems and assemblies for the U.S. Department of Defense, foreign military applications, and commercial markets. Its products are installed on a variety of United States military land vehicles, such as the Abrams and Bradley fighting vehicles, light armored and security vehicles, and have been selected for installation on the Stryker family of vehicles. The company's operating segment includes Optex Systems Richardson, Applied Optics Center Dallas, and others. It generates maximum revenue from the Optex Systems Richardson segment. Some of its products include M17 Day/Thermal Periscope; DDAN / M36 Sights; Laser Protected Periscopes; Muzzle Reference Sensor, and others.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).